Belderbos Bodine P S, de Wit Ronald, Hoop Esther Oomen-de, Nieuweboer Annemieke, Hamberg Paul, van Alphen Robbert J, Bergman André, van der Meer Nelly, Bins Sander, Mathijssen Ron H J, van Soest Robert J
Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, 3015 CE Rotterdam, The Netherlands.
Department of Internal Medicine, Franciscus Gasthuis and Vlietland, 3045 PM Rotterdam, The Netherlands.
Oncotarget. 2017 Nov 16;8(63):106468-106474. doi: 10.18632/oncotarget.22474. eCollection 2017 Dec 5.
Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel.
224 mCRPC patients were included in the current analysis. In multivariable analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and albumin were all significantly associated with OS. Hemoglobin and alkaline phosphatase were significantly associated with PSA response.
This study identified prognostic factors for OS and PSA response of men with mCRPC treated with cabazitaxel. In an increasingly complicated treatment landscape with several treatment options available our findings might serve to estimate the chance of survival of men qualifying for treatment with second-line chemotherapy in daily practice. Furthermore, these data can be used to risk-stratify patients in clinical trials.
We performed a post-hoc analysis of a randomized phase II trial of mCRPC patients treated with cabazitaxel. Cox and logistic regression models were used to investigate the influence of clinical and biochemical variables on OS and PSA response. Nomograms were developed to estimate the chance of PSA response and OS.
随着在疾病早期阶段引入新疗法，转移性去势抵抗性前列腺癌（mCRPC）男性患者的治疗选择变得越来越具有挑战性。本研究的目的是确定接受卡巴他赛治疗的mCRPC患者总生存期（OS）和前列腺特异抗原（PSA）反应的预后因素。
224例mCRPC患者纳入当前分析。在多变量分析中，世界卫生组织（WHO）体能状态、基线血红蛋白、碱性磷酸酶和白蛋白均与OS显著相关。血红蛋白和碱性磷酸酶与PSA反应显著相关。
本研究确定了接受卡巴他赛治疗的mCRPC男性患者OS和PSA反应的预后因素。在有多种治疗选择的日益复杂的治疗格局中，我们的研究结果可能有助于在日常实践中估计符合二线化疗治疗条件的男性患者的生存机会。此外，这些数据可用于在临床试验中对患者进行风险分层。
我们对接受卡巴他赛治疗的mCRPC患者的一项随机II期试验进行了事后分析。使用Cox和逻辑回归模型研究临床和生化变量对OS和PSA反应的影响。制定了列线图以估计PSA反应和OS的可能性。
